CompletedNot applicableNCT01255150

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

Background: \- Research has shown that the Epidermal Growth Factor Receptor (EGFR) gene is an important target for personalized lung cancer treatment. Individuals who have mutations in the EGFR gene have better responses when treated with certain personalized or targeted therapies compared with conventional chemotherapy. These mutations are more frequent in females with lung cancer who have never smoked, and different ethnic groups have different levels of frequency of the mutations. Researchers are interested in collecting more information on EGFR genetic mutations in Hispanics/Latinos with lung cancer, comparing the frequency of these mutations in males and females and smokers and nonsmokers. This study may lead to better, more personalized care approaches for all individuals with lung cancer. Objectives: \- To study the frequency of Epidermal Growth Factor Receptor mutations in Hispanic/Latino individuals who have been diagnosed with non-small cell lung cancer. Eligibility: \- Hispanic or Latino individuals who have been diagnosed with non-small cell lung cancer and who have lung tissue from a previous biopsy or surgery available for research purposes. Design: * Participants will provide consent for researchers to examine lung tissue collected from a previous biopsy or surgery. * Treatment will not be provided as part of this protocol.

Checked against the public recordLast updated Nov 21, 2019 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations12
SponsorNational Cancer Institute (NCI)
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
National Cancer Institute (NCI)
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

* INCLUSION CRITERIA: Hispanic or Latino\* patients with histologically confirmed non-small cell lung cancer. Hispanic or Latino\* patients with histologically confirmed non-small cell lung cancer. \* For the purpose of this study, the terms Hispanic or Latino is defined as an individual who either self identifies as Hispanic or Latino or was born in any Latin American country. Tumor samples from deceased Hispanic or Latino individuals with histologically confirmed non-small cell lung cancer for which basic clinical information is available Pathological waste or surplus stored identified or coded non-small cell lung cancer specimens from Hispanic or Latino individuals for which there is linked clinical information but the location of the person is not feasible to determine. EXCLUSION CRITERIA: Patients born in Europe, Asia, Africa or Australia are excluded.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Denver Health Medical CenterDenver, Colorado
  • National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland
  • Kettering Health NetworkKettering, Ohio
  • Oregon Health and Sciences Universtiy Cancer CenterPortland, Oregon
  • University of Texas Southwestern Medical CenterDallas, Texas
  • Universidad Mayor de San SimonCochabamba
  • Universidad de ColimaColima
  • Instituto Nacional de CancerologiaMexico City
  • Center for Research & Development in Health SciencesMonterrey
  • Universidad Autonoma de QueretaroQuerétaro
  • Instituto Nacional de Enfermedades Neoplasicas (INEN)Lima
  • Instituto de Oncologia Luis RazettiCaracas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 21, 2019. Always confirm current availability with the study team.

View original record ↗